NEOS Investment Management LLC Grows Stake in IDEXX Laboratories, Inc. $IDXX

Key Points

• NEOS Investment Management increased its IDEXX Laboratories stake by 12.5% in the second quarter, purchasing 6,721 additional shares and bringing its holdings to 60,354 shares valued at approximately $31.8 million. Institutional investors collectively own 87.84% of the company.
• Analysts maintain a generally positive outlook, with six Buy ratings and four Hold ratings producing a “Moderate Buy” consensus and an average price target of $747.00. Recent target changes ranged from $670 to $710.
• IDEXX exceeded quarterly expectations with $4.27 in earnings per share versus a $3.94 estimate and $1.22 billion in revenue, up 9.7% year over year. Shares opened at $535.38, near the company’s 52-week low of $518.55.

NEOS Investment Management LLC lifted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 12.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 60,354 shares of the company's stock after purchasing an additional 6,721 shares during the quarter. NEOS Investment Management LLC owned about 0.08% of IDEXX Laboratories worth $31,773,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. SHP Wealth Management bought a new position in IDEXX Laboratories in the 4th quarter worth about $26,000. Virtus Advisers LLC bought a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at about $26,000. J.Safra Asset Management Corp purchased a new position in shares of IDEXX Laboratories during the second quarter worth about $25,000. Elevation Wealth Partners LLC grew its holdings in shares of IDEXX Laboratories by 188.2% during the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company's stock worth $26,000 after purchasing an additional 32 shares in the last quarter. Finally, Wormser Freres Gestion increased its position in shares of IDEXX Laboratories by 671.4% in the fourth quarter. Wormser Freres Gestion now owns 54 shares of the company's stock worth $37,000 after purchasing an additional 47 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Wall Street Analysts Forecast Growth

IDXX has been the topic of a number of recent analyst reports. Citigroup raised their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a research note on Wednesday, August 5th. Weiss Ratings lowered shares of IDEXX Laboratories from a "hold (c+)" rating to a "hold (c)" rating in a report on Thursday, August 27th. UBS Group increased their price target on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a "neutral" rating in a report on Wednesday, August 5th. Wall Street Zen downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Sunday, July 12th. Finally, Barclays dropped their price objective on shares of IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating for the company in a report on Tuesday, August 11th. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $747.00.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock opened at $535.38 on Friday. The company has a fifty day moving average of $558.27 and a 200-day moving average of $570.47. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. IDEXX Laboratories, Inc. has a 52-week low of $518.55 and a 52-week high of $769.98. The stock has a market capitalization of $42.18 billion, a price-to-earnings ratio of 37.65, a price-to-earnings-growth ratio of 2.83 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, topping the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The firm had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.20 billion. During the same quarter in the previous year, the business earned $3.50 earnings per share. The company's quarterly revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Equities research analysts expect that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.